CTI BioPharma Corp. Total Assets 2011-2026 | CTIC

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets CTI BioPharma Corp.

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
126 M	72.4 M	58.2 M	46.3 M	89.8 M	54.9 M	63.8 M	144 M	92.3 M	93.7 M	73.7 M	62.2 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
144 M	46.3 M	81.5 M

Quarterly Total Assets CTI BioPharma Corp.

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
112 M	126 M	123 M	135 M	131 M	72.4 M	101 M	77.5 M	42.8 M	58.2 M	58.2 M	58.2 M	58.2 M	46.3 M	46.3 M	46.3 M	46.3 M	89.8 M	89.8 M	89.8 M	89.8 M	54.9 M	54.9 M	54.9 M	54.9 M	63.8 M	63.8 M	63.8 M	63.8 M	144 M	144 M	144 M	144 M	92.3 M	92.3 M	92.3 M	92.3 M	93.7 M	93.7 M	93.7 M	93.7 M	73.7 M	73.7 M	73.7 M	73.7 M	62.2 M	62.2 M	62.2 M	62.2 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
144 M	42.8 M	82.4 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Nanobiotix S.A. NBTX	67.8 M	$ 30.34	-0.82 %	$ 286 B	France
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Akebia Therapeutics AKBA	377 M	$ 1.4	-0.71 %	$ 360 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	22 B	$ 95.5	3.83 %	$ 27.2 B	Germany
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.92	-0.34 %	$ 6.35 B	Israel
Aytu BioScience AYTU	124 M	$ 2.55	-0.78 %	$ 16 M	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 20.37	-2.4 %	$ 952 M	USA
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
Aquestive Therapeutics AQST	160 M	$ 4.08	-2.16 %	$ 436 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Arcutis Biotherapeutics ARQT	433 M	$ 24.21	-1.47 %	$ 3.08 B	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Celldex Therapeutics CLDX	583 M	$ 32.24	-4.1 %	$ 2.14 B	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Cabaletta Bio CABA	165 M	$ 3.13	-1.26 %	$ 315 M	USA
Codiak BioSciences CDAK	172 M	-	-55.98 %	$ 2.15 M	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	215 M	-	-	$ 1.41 B	USA
InflaRx N.V. IFRX	55.2 M	$ 1.0	-2.91 %	$ 152 M	Germany
Immutep Limited IMMP	157 M	$ 0.31	-2.52 %	$ 1.08 B	Australia
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Concert Pharmaceuticals CNCE	165 M	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	47.9 M	$ 3.83	-2.3 %	$ 258 B	Britain
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Celsion Corporation CLSN	12.3 M	-	-6.63 %	$ 13.9 M	USA